New
HealthMore in Health→
Mitiperstat Misses Symptom and Exercise Endpoints in HFpEF Trial
Key Takeaways
- Phase 2b, multicenter, randomized, double-blind, placebo-controlled, three-arm trial of the MPO inhibitor mitiperstat in heart failure with ejection fraction above 40%.
- 711 patients (45% women) were randomized 1:1:1 to mitiperstat 2.5 mg, mitiperstat 5 mg or placebo, with 48 weeks of treatment.
- Co-primary endpoints at 16 weeks — KCCQ-TSS and 6-minute walk distance — both missed: placebo-corrected differences of –1.4 points (P = 0.29) and 3.8 m (P = 0.28).
- No secondary endpoint improved, including natriuretic peptides and inflammatory markers up to 48 weeks and echocardiographic parameters up to 24 weeks.
DE
DT Editorial Team··via nature.com